CD80-CD28 signaling controls the progression of inflammatory colorectal carcinogenesis

Oncotarget

Volumn 6, Issue 24, 2015, Pages 20058-20069

  Scarpa, Marco ^a   Brun, Paola ^b   Scarpa, Melania ^a   Morgan, Susan ^c   Porzionato, Andrea ^b   Kotsafti, Andromachi ^a   Bortolami, Marina ^b   Buda, Andrea ^b   D'Incà, Renata ^b   Macchi, Veronica ^b   Sturniolo, Giacomo C ^b   Rugge, Massimo ^b   Bardini, Romeo ^b   Castagliuolo, Ignazio ^b   Angriman, Imerio ^b   Castoro, Carlo ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Antigen presenting cells; CD8+ T cells; Colorectal carcinogenesis; Intestinal epithelial cells; Ulcerative colitis

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; HLA A ANTIGEN; MESALAZINE; RNA; STEROID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER CONTROL; CANCER INHIBITION; CARCINOGENESIS; CD8+ T LYMPHOCYTE; COHORT ANALYSIS; COLON ADENOCARCINOMA; COLON DISEASE; COLON DYSPLASIA; COLON MUCOSA; COLON RESECTION; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DYSPLASIA; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INTESTINE EPITHELIUM CELL; MAJOR CLINICAL STUDY; MALE; MESENTERY LYMPH NODE; MOUSE; NONHUMAN; PROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; ULCERATIVE COLITIS; ANIMAL; ANTIGEN PRESENTATION; C57BL MOUSE; COLON TUMOR; DISEASE COURSE; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PATHOLOGY; T LYMPHOCYTE;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD28; ANTIGENS, CD80; COLITIS, ULCERATIVE; COLONIC NEOPLASMS; DISEASE PROGRESSION; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84940212738     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2780     Document Type: Article

References (44)

1. Munkholm P. The incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 2003; 18:1-5.
2. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001; 48:526-535.
3. Lutgens MW, Vleggaar FP, Schipper ME, Stokkers PC, van der Woude CJ, Hommes DW, de Jong DJ, Dijkstra G, van Bodegraven AA, Oldenburg B, Samsom M. High frequency of early colorectal cancer in inflammatory bowel disease. Gut. 2008 Sep; 57:1246-51.
4. Itzkowitz S. Colon carcinogenesis in inflammatory bowel disease. J Clin Gastroenterol. 2003; 36:S70-4.
5. Serafino A, Moroni N, Zonfrillo M, Andreola F, Mercuri L, Nicotera G, Nunziata J, Ricci R, Antinori A, Rasi G, Pierimarchi P. WNT-pathway components as predictive markers useful for diagnosis, prevention and therapy in inflammatory bowel disease and sporadic colorectal cancer. Oncotarget. 2014 Feb 28; 5:978-92.
6. Van Assche G, Dignass A, Bokemeyer B, Danese S, Gionchetti P, Moser G, Beaugerie L, Gomollón F, Häuser W, Herrlinger K, Oldenburg B, Panes J, Portela F, et al; European Crohn's and Colitis Organisation. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis. 2013 Feb; 7:1-33.
7. Lim CH, Dixon MF, Vail A, Forman D, Lynch DA, Axon AT. Ten year follow up of ulcerative colitis patients with and without low grade dysplasia. Gut. 2003 Aug; 52:1127-32.
8. Lynch DA, Lobo AJ, Sobala GM, Dixon MF, Axon AT. Failure of colonoscopic surveillance in ulcerative colitis. Gut. 1993 Aug; 34:1075-80.
9. Kiran RP, Ahmed Ali U, Nisar PJ, Khoury W, Gu J, Shen B, Remzi FH, Hammel JP, Lavery IC, Fazio VW, Goldblum JR. Risk and location of cancer in patients with preoperative colitis-associated dysplasia undergoing proctocolectomy. Ann Surg. 2014 Feb; 259:302-9.
10. Zisman TL, Bronner MP, Rulyak S, Kowdley KV, Saunders M, Lee SD, Ko C, Kimmey MB, Stevens A, Maurer J, Brentnall TA. Prospective study of the progression of low-grade dysplasia in ulcerative colitis using current cancer surveillance guidelines. Inflamm Bowel Dis. 2012 Dec; 18:2240-6.
11. Dunn GP, Koebel CM, Schreiber R.D. Interferons, immunity and cancer immunoediting. Nat Rev Immunol. 2006; 6:836-848.
12. Chen L, Ashe S, Brady WA, Hellström I, Hellström KE, Ledbetter JA, McGowan P, Linsley PS. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell. 1992 Dec 24; 71:1093-102.
13. Janeway CA, Bottomly K. Signals and signs for lymphocyte responses. Cell. 1994; 76:275-285.
14. Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science. 1990; 248:1349-1356.
15. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996; 271:1734-1736.
16. Antonia SJ, Muñoz-Antonia T, Soldevila G, Miller J, Flavell RA. B7-1 expression by a non-antigen presenting cell-derived tumor. Cancer Res. 1995 Jun 1; 55:2253-6.
17. Scarpa M, Cardin R, Bortolami M, Kotsafti A, Scarpa MC, Pozza A, Maran G, Picciocchi M, Ruffolo C, D'Incà R, Sturniolo GC, Castagliuolo I, Castoro C, et al. Mucosal immune environment in colonic carcinogenesis: CD80 expression is associated to oxidative DNA damage and TLR4-NFκB signalling. Eur J Cancer. 2013; Jan 49:254-63.
18. Scarpa M, Behboo R, Angriman I, Cecchetto A, D'Incà R, Termini B, Barollo M, Ruffolo C, Polese L, Sturniolo GC, D'Amico DF. Expression of costimulatory molecule CD80 in colonic dysplasia in ulcerative colitis: an immunosurveillance mechanism against colorectal cancer?. Int J Colorectal Dis. 2006 Dec; 21:776-83.
19. Koch M, Beckhove P, Op den Winkel J, Autenrieth D, Wagner P, Nummer D, Specht S, Antolovic D, Galindo L, Schmitz-Winnenthal FH, Schirrmacher V, Büchler MW, Weitz J. Tumor infiltrating T lymphocytes in colorectal cancer: Tumor-selective activation and cytotoxic activity in situ. Ann Surg. 2006 Dec; 244:986-92; discussion 992-3.
20. Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005 Dec 22; 353:2654-66.
21. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res. 1970; 13:1-27.
22. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002 Nov; 3:991-8.
23. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ, Schreiber RD. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007 Dec 6; 450:903-7.
24. Pages F, Galon J, Fridman WH. The essential role of the in situ immune reaction in human colorectal cancer. J Leukocyte Biol. 2008; 84:981-987.
25. Scarpa M, Bortolami M, Cecchetto A, Faggian D, Kotsafti A, Ruffolo C, Navaglia F, Pozza A, D'Incà R, Plebani M, Sturniolo GC, Angriman I. Mucosal immune environment in colonic carcinogenesis: CD80 up-regulation in colonic dysplasia in ulcerative colitis. Eur J Cancer. 2011 Mar; 47:611-9.
26. Watanabe T, Kobunai T, Yamamoto Y, Ikeuchi H, Matsuda K, Ishihara S, Nozawa K, Iinuma H, Kanazawa T, Tanaka T, Yokoyama T, Konishi T, Eshima K, et al. Predicting ulcerative colitis-associated colorectal cancer using reverse-transcription polymerase chain reaction analysis. Clin Colorectal Cancer. 2011 Jun; 10:134-41.
27. Evans EJ, Esnouf RM, Manso-Sancho R, Gilbert RJ, James JR, Yu C, Fennelly JA, Vowles C, Hanke T, Walse B, Hünig T, Sørensen P, Stuart DI, et al. Crystal structure of a soluble CD28-Fab complex. Nat Immunol. 2005 Mar; 6:271-9.
28. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006 Sep 29; 313:1960-4.
29. Pardoll DM. The blockade of immune checkpoint in cancer immunotherapy. Nat Rev Cancer. 2012; 12:252-264.
30. Hodge JW, Abrams S, Schiom J, Kantor JA. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res. 1994; 54:5552-5555.
31. Helbling M, Lukesch A, Haimovici A, Karamitopoulou E, Berger MD, Hädrich M, Mallaev M, Schnüriger B, Koelzer VH, Dawson H, Borner M, Langer R, Rosenberg R, et al. Investigation of IL-23 (p19, p40) and IL-23R identifies nuclear expression of IL-23 p19 as a favorable prognostic factor in colorectal cancer: a retrospective multicenter study of 67 patients. Oncotarget. 2014 Jul 15; 5:4671-82.
32. Malavasi F, Deaglio S, Funaro A, Ferrero E, Horenstein AL, Ortolan E, Vaisitti T, Aydin S. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol Rev. 2008 Jul; 88:841-86.
33. Karlsson M, Lindberg K, Karlén P, Ost A, Thörn M, Winqvist O, Eberhardson M. Evidence for immunosurveillance in intestinal premalignant lesions. Scand J Immunol. 2010 May; 71:362-8.
34. De Robertis M, Massi E, Poeta ML, Carotti S, Morini S, Cecchetelli L, Signori E, Fazio VM. The AOM/DSS murine model for the study of colon carcinogenesis: From pathways to diagnosis and therapy studies. J Carcinog. 2011 Mar 24; 10:9.
35. Eri R, Kodumudi KN, Summerlin DJ, Srinivasan M. Suppression of colon inflammation by CD80 blockade: evaluation in two murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008 Apr; 14:458-70.
36. Rudd CE, Taylor A, Scheider H. CD28 and CTLA4 coreceptor expression and signal transduction. Immunol Rev. 2009; 229:12-26.
37. McDermott D, Haanen J, Chen TT, Lorigan P. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Ann Oncol. 2013 Oct; 24:2694-8.
38. Zang X, Allison JP. The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res. 2007; 13:5271-9.
39. Chung KY, Gore I, Fong L, Venook A, Beck SB, Dorazio P, Criscitiello PJ, Healey DI, Huang B, Gomez-Navarro J, Saltz LB. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J Clin Oncol. 2010 Jul 20; 28:3485-90.
40. Grossmann J, Walther K, Artinger M, Kiessling S, Steinkamp M, Schmautz WK, Stadler F, Bataille F, Schultz M, Schölmerich J, Rogler G. Progress on isolation and short-term ex-vivo culture of highly purified nonapoptotic human intestinal epithelial cells (IEC). Eur J Cell Biol. 2003 May; 82:262-70.
41. Srinivasan M, Summerlin DJ. Modulation of the colonic epithelial cell responses and amelioration of inflammation by CD80 blockade in TNBS colitis. Clin Immunol. 2009; 133:411-421.
42. Florén CH, Benoni C, Willén R. Histologic and colonoscopic assessment of disease extension in ulcerative colitis. Scand J Gastroenterol. 1987; 22:459-462.
43. Schlemper RJ, Riddell RH, Kato Y, Borchard F, Cooper HS, Dawsey SM, Dixon MF, Fenoglio-Preiser CM, Fléjou JF, Geboes K, Hattori T, Hirota T, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut. 2000 Aug; 47:251-5.
44. Zisman TL, Bronner MP, Rulyak S, Kowdley KV, Saunders M, Lee SD, Ko C, Kimmey MB, Stevens A, Maurer J, Brentnall TA. Prospective study of the progression of low-grade dysplasia in ulcerative colitis using current cancer surveillance guidelines. Inflamm Bowel Dis. 2012 Dec; 18:2240-6.